GetReal: launch of EU-funded project to get real life data into drug development
11.03.2014
Once a new drug has been developed, it must be reviewed by both the regulators and health technology assessment (HTA) bodies. The regulators draw on data, mostly from clinical trials, to determine if a drug is safe and works well enough to be authorised for use in patients. For their part, HTA organisations assess the drug’s ‘relative effectiveness’, which is the extent to which a treatment does more good than harm when compared to one or more alternative treatments when provided under normal healthcare circumstances. Read more